Search results

519 items matching your search terms.
Filter the results.
Item type













New items since



Sort by relevance · date (newest first) · alphabetically
Alliance for Cancer Gene Therapy (ACGT): 2015 Investigator's Award in Clinical Translation of Cell and Gene Therapy for Sarcoma
ACGT has released an RFP for research aimed at furthering the development of cell and gene therapy approaches to the treatment of cancer. This award is specifically for those conducting cell and gene therapy research for sarcoma. Award amount is up to $500,000 over 2-3 years. LOI deadline is Oct. 26, 2015 by 11 a.m.
Located in Vital Signs / 2015 / Sept. 17
Alliance for Lupus Research & Pfizer's Centers for Therapeutic Innovation: Challenge Grant Program
The ALR and Pfizer are accepting applications to support research that facilitates and accelerates development of new therapies for lupus patients. Awards are intended for studies of high scientific merit and translational potential focused on the role of interferon-beta in the pathogenesis and/or maintenance of SLE. Award amount is up to $150,000 per year for two years. Application deadline is April 1 by 5 p.m.
Located in Vital Signs / 2016 / March 10
Allied-Bristol Life Sciences: CATALYST
Allied-Bristol Life Sciences (ABLS) is a joint venture of global pharmaceutical company Bristol-Myers Squibb and venture builder Allied Minds. Together, they have launched CATALYST, a new program designed to identify and develop commercially-promising biopharmaceutical innovations from leading universities and research institutions. The award amount varies. Application deadline is rolling.
Located in Vital Signs / 2017 / Feb. 2
Alpha Foundation for the Improvement of Mine Safety and Health, Inc. - Call for Proposals
The Alpha Foundation supports research projects that have practical implications on mine safety and health for workers, operators and policymakers. Emphasis is placed on early transition and rapid dissemination of project findings. Concept paper deadline is Feb. 1, 2016.
Located in Vital Signs / 2016 / Jan. 7
Alpha-1 Foundation: Effect of Augmentation Therapy on COPD Exacerbations in Alpha-1 Antitrypsin Deficiency
The Alpha-1 Foundation is accepting applications to assess the effect of intravenous augmentation therapy compared to placebo on acute pulmonary exacerbations (frequency and/or severity and/or time to first exacerbation) in patients with severe alpha-1 antitrypsin deficiency (serum alpha-1 antitrypsin level <50mg/dl when clinically stable). Award amount is up to $250,000 per year for up to two years. The application deadline is May 8, 2017.
Located in Vital Signs / 2017 / April 27
Alport Syndrome Foundation: 2016 Request for Proposals
A collaboration between the Alpert Syndrome Foundation, Inc., Pederson Family and the Kidney Foundations of Canada (KFOC), the 2016 RFP is accepting applications to fund basic science and clinical research on the natural history, biochemical basis and treatment of Alport Syndrome. Award amount is up to $100,000 over one- to two-year projects. Application deadline is March 21, by 7 p.m.
Located in Vital Signs / 2016 / Feb. 25
Alport Syndrome Foundation: 2017 Request for Proposals
A collaboration between the Alport Syndrome Foundation, Inc., Pederson Family and the Kidney Foundations of Canada (KFOC), the 2017 RFP is accepting applications to fund research that will find novel treatments to prevent kidney failure and hearing loss in all patients with Alport Syndrome. Research proposals with the potential to accelerate the development of new treatments to prolong kidney function and prevent hearing loss including: Identification and investigation of target pathways in disease progression; and Drug repurposing of existing approved drugs or other new approaches to improve the current standard of care. The award amount is up to $100,000 for up to two years. The application deadline is March 20, 2017 by 5:00pm MST.
Located in Vital Signs / 2017 / Feb. 16
Alternatives Research & Development Foundation: 2016 Alternatives Research Grant Program
The Foundation is accepting applications for projects that will significantly reduce or replace laboratory animals in biomedical research, product safety testing, or educational demonstrations. Award amount is up to $40,000. Application deadline is May 2.
Located in Vital Signs / 2016 / Feb. 18
Alzheimer's Drug Discovery Foundation: 2017 Preclinical Drug Discovery
The Alzheimer’s Drug Discovery Foundation (ADDF) is accepting Letters of Intent (LOIs) that seek to fill the critical translational funding gap between basic research and later stage drug development by funding preclinical drug discovery and biomarker development programs relevant to Alzheimer’s disease, related dementias and cognitive aging. Award amount is up to $600,000 for one (1) year. The LOI deadline is May 19, 2017.
Located in Vital Signs / 2017 / April 27
Alzheimer's Drug Discovery Foundation, Program to Accelerate Clinical Trials
UPCOMING DEADLINE: The Alzheimer’s Drug Discovery Foundation (ADDF) is accepting Letters of Intent (LOIs) with the goal to increase the number of innovative treatments tested in humans for Alzheimer’s disease and related dementias. Award amount up to $3,000,000, based on stage and scope of research. The LOI deadline is April 13, 2018 by 5:00pm EST.
Located in Vital Signs / 2018 / April 5